Allogene Competitors

Stocks . USA . 
Stock . Allogene Therapeutics
ALLO Stock  USD 1.59  0.14  9.66%   
Allogene Therapeutics competes with Editas Medicine, Cabaletta Bio, Caribou Biosciences, Atea Pharmaceuticals, and Humacyte; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Allogene Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Allogene Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Allogene Therapeutics Correlation with its peers.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Allogene Therapeutics vs Immutep Correlation

Poor diversification

The correlation between Allogene Therapeutics and IMMP is 0.71 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Allogene Therapeutics and IMMP in the same portfolio, assuming nothing else is changed.

Moving against Allogene Stock

  0.54NIO Nio Class APairCorr
  0.5GRAB Grab HoldingsPairCorr
  0.4NVDA NVIDIA Aggressive PushPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.081.596.81
Details
Intrinsic
Valuation
LowRealHigh
0.071.496.71
Details
Naive
Forecast
LowNextHigh
0.031.396.61
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.261.521.79
Details

Allogene Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Allogene Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Allogene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Allogene Therapeutics does not affect the price movement of the other competitor.

High positive correlations

IMMP
+ 0.94
VNDA
CRBU
+ 0.9
EDIT
HUMA
+ 0.88
CRBU
HUMA
+ 0.82
EDIT
VYGR
+ 0.77
EDIT
KYTX
+ 0.76
VNDA
  

High negative correlations

VNDA
- 0.83
CRBU
VNDA
- 0.78
EDIT
IMMP
- 0.77
CRBU
VNDA
- 0.75
HUMA
IMMP
- 0.75
EDIT
IMMP
- 0.71
HUMA

Risk-Adjusted Indicators

There is a big difference between Allogene Stock performing well and Allogene Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Allogene Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EDIT  3.17 (0.66) 0.00 (0.34) 0.00 
 0.00 
 6.56 
(8.18)
 21.57 
CABA  4.10 (0.33) 0.00 (0.32) 0.00 
 0.00 
 8.16 
(7.27)
 32.87 
CRBU  3.07 (0.88) 0.00 (0.25) 0.00 
 0.00 
 6.86 
(6.41)
 20.16 
AVIR  2.22  0.30  0.08  0.40  3.19 
(2.29)
 4.64 
(4.43)
 17.79 
HUMA  3.84 (0.80) 0.00 (0.30) 0.00 
 0.00 
 8.16 
(8.13)
 20.54 
VNDA  3.70  1.16  0.24 (1.03) 3.59 
(4.22)
 11.39 
(5.84)
 39.51 
VYGR  2.46 (0.27) 0.00 (0.20) 0.00 
 0.00 
 4.58 
(5.23)
 19.71 
KYTX  5.95  0.56  0.06  0.75  8.31 
(6.28)
 9.57 
(9.70)
 55.75 
ACHV  3.20 (0.31) 0.00 (0.08) 0.00 
 0.00 
 5.86 
(5.87)
 25.05 
IMMP  3.46  0.79  0.23  0.80  3.00 
(4.10)
 7.41 
(5.41)
 31.54 

Allogene Therapeutics Competitive Analysis

The better you understand Allogene Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Allogene Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Allogene Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALLO EDIT CABA CRBU AVIR HUMA VNDA VYGR KYTX ACHV
 9.66 
 1.59 
Allogene
 2.37 
 2.06 
Editas
 3.51 
 2.75 
Cabaletta
 2.63 
 1.48 
Caribou
 1.03 
 3.91 
Atea
 3.00 
 1.03 
Humacyte
 1.17 
 7.78 
Vanda
 0.25 
 3.98 
Voyager
 2.03 
 8.21 
Kyverna
 0.46 
 4.34 
Achieve
Market Volatility
(90 Days Market Risk)
Dangerous
Very risky
Dangerous
Dangerous
Relatively risky
Extremely Dangerous
Relatively risky
Relatively risky
Unstable
Unstable
Market Performance
(90 Days Performance)
Fair
Weakest
Weakest
Weakest
Fair
Weakest
Good
Weakest
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Risky
Low
High
Small
Risky
Low
Small
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Sell
Sell
Current Ratio
11.42
12.67
15.22
12.23
27.46
17.46
5.62
1.55
N/A
5.81
Net Asset
548.71 M
341.59 M
185.05 M
313.31 M
464.67 M
137.87 M
656.2 M
393.05 M
304.64 M
38.63 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
-0.4
N/A
N/A
N/A
EBITDA
(243.33 M)
(233.11 M)
(110.3 M)
(162.69 M)
(131.8 M)
(132.23 M)
(32.53 M)
(78.56 M)
(125.2 M)
(37.42 M)
Current Valuation
168.78 M
55.1 M
140.69 M
23.08 M
(25.52 M)
209.12 M
191.12 M
206.13 M
387.04 M
207.25 M
Price To Book
1.09
14.95
1.97
1.02
0.96
70.17
1.02
1.0
3.48
7.3
Operating Margin
N/A
-3.25
N/A
-13.38
N/A
-32.39
-0.56
-2.29
N/A
N/A
Retained Earnings
(1.82 B)
(1.47 B)
(349.1 M)
(448.39 M)
(364.22 M)
(686.01 M)
(174.29 M)
(326.18 M)
(263.52 M)
(205.58 M)
Current Asset
418.72 M
144.99 M
30.42 M
N/A
97.88 M
N/A
166.55 M
195.89 M
N/A
22.54 M
Beta
0.52
2.16
3.25
2.62
0.08
1.93
0.61
1.28
N/A
1.72
Number Of Employees
226
246
148
147
56
218
368
172
129
25
Shares Outstanding
224.73 M
97.62 M
96.27 M
93.47 M
78.13 M
193 M
59.1 M
55.6 M
59.61 M
53.23 M
Cash Flow From Operations
(200.3 M)
(210.28 M)
(88.22 M)
(138.2 M)
(135.5 M)
(98.12 M)
(15.76 M)
(15.31 M)
(114.25 M)
(29.77 M)
Total Debt
90.76 M
35.03 M
15.6 M
26.49 M
1.64 M
16.54 M
12.36 M
43.73 M
8.24 M
9.96 M
Return On Equity
-0.54
-2.11
-1.01
-0.74
-0.38
-2.5
-0.17
-0.46
-0.71
-1.61
Return On Asset
-0.27
-0.28
-0.52
-0.32
-0.24
-0.63
-0.12
-0.25
-0.41
-0.65
Number Of Shares Shorted
18.63 M
11.83 M
18.44 M
6.79 M
7.3 M
37.15 M
2.88 M
3.45 M
3.41 M
6.82 M
Book Value Per Share
1.41
0.14
1.45
1.52
4.04
-0.03
7.89
3.96
3.47
0.64
Current Liabilities
26.36 M
6.92 M
843.74 K
N/A
6.25 M
N/A
51.32 M
23.93 M
N/A
9.1 M
Total Asset
548.71 M
341.59 M
185.05 M
313.31 M
464.67 M
137.87 M
656.2 M
393.05 M
304.64 M
38.63 M
Debt To Equity
0.13
0.043
-3.76
0.08
0.005
0.36
0.022
0.4
N/A
1.18
Short Ratio
4.72
6.44
10.43
6.57
18.82
7.63
1.01
6.8
1.33
11.02
Target Price
7.38
5.43
13.13
10.88
7.67
7.71
13.63
15.0
29.6
15.38
Shares Owned By Institutions
63.5
47.3
74.32
39.07
73.19
24.0
74.96
57.05
54.12
40.65
Market Capitalization
325.86 M
205.98 M
274.36 M
144.88 M
302.35 M
198.79 M
454.45 M
220.73 M
553.15 M
245.41 M
Price To Earning
-3.3
-7.02
-3.33
N/A
15.03
18.04
24.83
5.62
N/A
-0.03
Price To Earnings To Growth
-4.18
N/A
N/A
0.5
N/A
N/A
-2.42
N/A
N/A
N/A
Price To Sales
11631.14
4.44
N/A
15.59
1.9
126.53
2.14
7.05
N/A
N/A
Net Income
(257.59 M)
(237.09 M)
(115.86 M)
(149.1 M)
(168.38 M)
(148.7 M)
(18.9 M)
(65 M)
(127.48 M)
(39.83 M)
Earnings Per Share
-0.98
-2.35
-2.4
-1.7
-1.77
-0.27
-1.44
-2.17
-3.73
-1.35
Shares Owned By Insiders
16.7
0.27
1.57
9.71
12.91
16.36
7.21
16.12
9.1
4.36
Revenue
22 K
32.31 M
N/A
9.99 M
N/A
N/A
198.77 M
80 M
N/A
N/A
Working Capital
267.86 M
212.09 M
139.59 M
188.73 M
443.75 M
27.91 M
338.91 M
227.02 M
256.85 M
29.79 M
Cash And Equivalents
490.49 M
452.56 M
96.81 M
339.92 M
684.48 M
189.04 M
440.86 M
148.06 M
N/A
29.38 M
Cash Per Share
3.41
6.59
3.34
5.59
8.22
1.84
7.79
3.83
N/A
3.03
Gross Profit
(166.49 M)
(64.78 M)
N/A
(119.26 M)
(120.09 M)
(73.8 M)
200.27 M
(102.99 M)
(137.19 M)
N/A
Day Typical Price
1.54
2.06
2.75
1.49
3.87
1.02
7.78
3.98
8.23
4.34
Accumulation Distribution
649811.0
62780.95
184517.0
25663.96
20424.51
179397.0
22886.61
39152.25
34593.49
36542.6
Daily Balance Of Power
1.0
(0.50)
(0.53)
(0.67)
0.2353
0.4286
0.3462
0.0455
(0.40)
(0.11)
Period Momentum Indicator
0.14
(0.05)
(0.10)
(0.04)
0.04
0.03
0.09
0.01
(0.17)
(0.02)
Rate Of Daily Change
1.1
0.98
0.96
0.97
1.01
1.03
1.01
1.0
0.98
1.0
Day Median Price
1.52
2.06
2.75
1.5
3.86
1.02
7.78
3.98
8.24
4.34
Price Action Indicator
0.14
(0.03)
(0.04)
(0.04)
0.075
0.03
0.045
0.005
(0.11)
(0.01)
Relative Strength Index
54.29
41.7
51.36
38.25
59.5
41.44
58.05
46.11
49.12
41.04
Coefficient Of Variation
966.76
(779.15)
(2,132)
(573.91)
938.05
(726.90)
529.29
(1,691)
1325.98
(2,435)
Mean Deviation
3.95
3.17
4.1
3.07
2.22
3.84
3.7
2.46
5.95
3.2
Jensen Alpha
0.4362
(0.66)
(0.33)
(0.88)
0.3047
(0.80)
1.16
(0.27)
0.5551
(0.31)
Total Risk Alpha
0.1611
(0.88)
(0.71)
(1.02)
0.1112
(1.03)
0.6906
(0.46)
0.0282
(0.50)
Sortino Ratio
0.0998
N/A
N/A
N/A
0.0776
N/A
0.2416
N/A
0.063
N/A
Downside Variance
22.98
N/A
N/A
N/A
14.75
N/A
19.18
N/A
74.8
N/A
Standard Deviation
5.22
4.39
5.92
4.12
3.37
4.89
5.92
3.45
8.04
4.35
Kurtosis
0.7093
1.36
5.61
0.7792
5.49
0.6885
6.35
2.8
4.15
2.14
Potential Upside
9.76
6.56
8.16
6.86
4.64
8.16
11.39
4.58
9.57
5.86
Treynor Ratio
0.2903
(0.34)
(0.32)
(0.25)
0.4005
(0.30)
(1.03)
(0.20)
0.7453
(0.08)
Maximum Drawdown
26.97
21.57
32.87
20.16
17.79
20.54
39.51
19.71
55.75
25.05
Variance
27.24
19.26
35.09
17.0
11.37
23.9
35.09
11.88
64.59
18.89
Market Risk Adjusted Performance
0.3003
(0.33)
(0.31)
(0.24)
0.4105
(0.29)
(1.02)
(0.19)
0.7553
(0.07)
Risk Adjusted Performance
0.0837
(0.08)
(0.03)
(0.12)
0.0852
(0.09)
0.1459
(0.04)
0.0638
(0.02)
Skewness
0.5155
0.5805
1.17
(0.03)
0.0188
0.5965
1.73
0.5805
(0.85)
0.5154
Semi Deviation
3.98
N/A
N/A
N/A
3.19
N/A
3.59
N/A
8.31
N/A
Information Ratio
0.0917
(0.14)
(0.06)
(0.19)
0.0884
(0.15)
0.1786
(0.08)
0.0678
(0.06)
Value At Risk
(6.16)
(8.18)
(7.27)
(6.41)
(4.43)
(8.13)
(5.84)
(5.23)
(9.70)
(5.87)
Expected Short fall
(5.36)
N/A
N/A
N/A
(2.29)
N/A
(4.22)
N/A
(6.28)
N/A
Downside Deviation
4.79
N/A
N/A
N/A
3.84
N/A
4.38
N/A
8.65
N/A
Semi Variance
15.86
N/A
N/A
N/A
10.18
N/A
12.9
N/A
69.02
N/A

Allogene Therapeutics Competition Performance Charts

Five steps to successful analysis of Allogene Therapeutics Competition

Allogene Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Allogene Therapeutics in relation to its competition. Allogene Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Allogene Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Allogene Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Allogene Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Allogene Therapeutics position

In addition to having Allogene Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tips ETFs Thematic Idea Now

Tips ETFs
Tips ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Tips ETFs theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tips ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
How To Invest In Allogene
Details
Is Allogene Stock a good investment?
Details
What is Allogene Therapeutics' Net Worth?
Details
Top Sectors
View
Check out Allogene Therapeutics Correlation with its peers.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Stock sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY